Want to see CMMB full AI Analyst Report?
CMMB Stock Chart & Stats
$1.36
$0.04(2.94%)
At close: 4:00 PM EDT
$1.36
$0.04(2.94%)
Day’s Range― - ―
52-Week Range$1.35 - $4.12
Previous CloseN/A
Volume17.83K
Average Volume (3M)207.96K
Market Cap
$13.82M
Enterprise Value$4.48
Total Cash (Recent Filing)$8.04M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Nov 06, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.10
Shares Outstanding7,200,378
10 Day Avg. Volume363,095
30 Day Avg. Volume207,955
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.85
Price to Sales (P/S)0.00
P/FCF Ratio-0.94
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$5.00Price Target Upside267.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.02
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Merger And Pipeline ExpansionThe proposed merger could broaden Chemomab’s clinical and commercial platform by adding Scipher’s precision-medicine capabilities, revenue streams and AI-guided development approach. This may improve indication selection and create a more diversified long-term pipeline.
Low Balance-Sheet LeverageMinimal debt limits interest obligations and reduces creditor pressure while the company funds clinical development. A lightly levered balance sheet provides greater flexibility to allocate capital toward trials, partnerships and strategic transactions rather than debt service.
Improving Loss And Cash-Burn TrendsImproved losses and lower cash burn suggest emerging expense discipline in the R&D model. Although the company remains unprofitable, sustained operating control could extend runway and increase the value of future financing or partnering proceeds.
Bears Say
Pre-Revenue Business ModelWithout demonstrated product revenue, Chemomab lacks internally generated commercial funding and remains dependent on clinical progress to establish future value. Delays, weak efficacy or failed trials could prolong the period before the pipeline supports durable revenue.
Ongoing Cash Burn And Financing DependencePersistent cash consumption means continued external financing is likely required to advance clinical programs. Repeated capital raises can dilute existing holders and may become more difficult or costly if development milestones do not improve funding access.
Asset And Equity ErosionThe decline in assets and shareholders’ equity shows that operating losses are consuming the company’s financial base. Continued erosion reduces strategic flexibility and increases the importance of securing financing, partnerships or successful clinical outcomes.
Chemomab Therapeutics News
CMMB FAQ
What was Chemomab Therapeutics’s price range in the past 12 months?
Chemomab Therapeutics lowest stock price was $1.35 and its highest was $4.12 in the past 12 months.
What is Chemomab Therapeutics’s market cap?
Chemomab Therapeutics’s market cap is $13.82M.
When is Chemomab Therapeutics’s upcoming earnings report date?
Chemomab Therapeutics’s upcoming earnings report date is Nov 06, 2026 which is in 78 days.
How were Chemomab Therapeutics’s earnings last quarter?
Chemomab Therapeutics released its earnings results on Aug 19, 2026. The company reported -$0.003 earnings per share for the quarter, beating the consensus estimate of -$0.15 by $0.147.
Is Chemomab Therapeutics overvalued?
According to Wall Street analysts Chemomab Therapeutics’s price is currently Undervalued.
Does Chemomab Therapeutics pay dividends?
Chemomab Therapeutics does not currently pay dividends.
What is Chemomab Therapeutics’s EPS estimate?
Chemomab Therapeutics’s EPS estimate is 0.
How many shares outstanding does Chemomab Therapeutics have?
Chemomab Therapeutics has 7,200,378 shares outstanding.
What happened to Chemomab Therapeutics’s price movement after its last earnings report?
Chemomab Therapeutics reported an EPS of -$0.003 in its last earnings report, beating expectations of -$0.15. Following the earnings report the stock price went up 9.424%.
Which hedge fund is a major shareholder of Chemomab Therapeutics?
Currently, no hedge funds are holding shares in CMMB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chemomab Therapeutics
Chemomab Therapeutics Ltd. operates as a clinical-stage biotechnology firm, dedicated to identifying and advancing novel treatments for inflammatory and fibrotic conditions. Its leading experimental drug candidate, CM-101, is a humanized monoclonal antibody specifically engineered to impede the core function of soluble chemokine CCL24. This potential therapy is currently under investigation for its efficacy in managing primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc). Established in 2011, the company, formerly known as Anchiano Therapeutics Ltd., adopted its current name, Chemomab Therapeutics Ltd., in March 2021 and is headquartered in Tel Aviv, Israel.
CMMB Stock 12 Month Forecast
Average Price Target
$5.00
▲(267.65% Upside)